Bryan Garnier - Mister Spex (MRXG) Mister Spex: Governance crisis intensifies

Report

Bryan Garnier

Cedric Rossi

Mister Spex: Governance crisis intensifies

Yesterday evening, MRX announced that founder and CEO Dirk Graber would step down on 31st July and hand over to CFO Stephan Schulz-Gohritz. This major announcement comes after a hectic AGM last month and the surprise resignations of two members of the Supervisory Board earlier this month (see our W

17/07/2024 1 EN

Underlying

Mister Spex

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Cedric Rossi

Other Reports on these Companies

Bryan Garnier

OTC hearing aid market: no worms in the Apple

Among all the innovative products presented at Monday's Apple Keynote, the AirPods Pro 2 stood out for the new OTC hearing aid capability to be included for users with mild to moderate hearing loss, representing EUR1.4bn people globally. While most hearing aid stocks and, to a lesser extent, Essilo

September 11, 2024 September 11, 2024 1 EN

Bryan Garnier

FIE & MRX: distinct H1 trajectories

Yesterday, Fielmann (FIE) and Mister Spex (MRX) both reported their final H1 2024 results which were in line with their respective pre-announced figures. Arguably, Germany remains their largest market with a revenue share of 73% and 75% respectively but the market's focus has differed in recent mon

August 30, 2024 August 30, 2024 1 EN

Bryan Garnier

Mister Spex: short-term pain, long-term gain

As part of a new restructuring programme announced yesterday, MRX will close its nine International stores which have struggled to reach the same profitability levels as its store network in Germany. Beyond a negative EUR9m impact on top of initial FCF guidance for -EUR12 to -EUR16m, MRX is also re

August 15, 2024 August 15, 2024 1 EN

Basilea pipeline validated by US BARDA, guidance upgraded

Basilea today lifted FY24 guidance, raising net profit by whopping 43% (CHF 60m versus previous CHF 42m) and revenue by 3.6% following the decision of the US BARDA agency to support Basilea pipeline development with an initial USD 29m funding, of which Basilea intends to recognize CHF 7m in H2 24.

21h / 12m 21h / 12m 1 EN

Maria Vara

Maria Vara

ONWARD Medical: third successful ARC BCI implantation!

We are pleased to see that clinical developments on the BCI front are running smoothly! This morning, ONWARD announced that it has successfully implanted the ARC-BCI system in another SCI participant aiming to restore lower limb mobility. As was planned according to the EIC funding granted in 2022,

21h / 18m 21h / 18m 1 EN

Maria Vara

Maria Vara

BICO: CMD takeaways, a new vision amid tough market

Yesterday, BICO held a Capital Markets Day (CMD) where the new top executive management team provided an in-depth view of the renewed BICO 2.0 strategy. Aware of the Life Science (LS) Tools and Bioconvergence post-pandemic tough market conditions, the company's new vision focuses on Lab Automation

September 18, 2024 September 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Mister Spex: Governance crisis intensifies

OTC hearing aid market: no worms in the Apple

FIE & MRX: distinct H1 trajectories

Mister Spex: short-term pain, long-term gain

Basilea pipeline validated by US BARDA, guidance upgraded

ONWARD Medical: third successful ARC BCI implantation!

BICO: CMD takeaways, a new vision amid tough market

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe